videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Embla Medical

This morning, Össur released its Q3 2023 results. Together with, Össur’s management, went through the results and the expectations for the rest of the year and gave a short introduction to the company,
 

This morning, &Ouml;ssur released its Q3 2023 results, &Ouml;ssur realized 7% organic growth in Q3 2023 and 9% for the first 9 months of 2023. Growth in the quarter was primarily driven by the sales in prosthetics and patient care, and regionally by the Americas and EMEA. The company realized an EBITDA margin of 18% year-to-date, which is the same level as in 2022. Compared to analyst expectations for the quarter, sales are marginally below, while operating earnings are slightly better than expected. 
The company's net interest-bearing debt relative to EBITDA ends at 2.9x, marginally below its target level of 2-3x. Share buybacks remain on pause. 
The 2023 guidance was revised upwards earlier this year and is maintained in connection with the Q3 reporting. Organic growth is expected to be at 7-8% (9% for the first 9 months) and the EBITDA margin is expected at the level of 17-20% (18% for the first 9 months). Today, we together with, &Ouml;ssur&rsquo;s management, went through the results and the expectations for the rest of the year and gave a short introduction to the company.
&Ouml;ssur is a leading global provider of innovative mobility solutions in the medical technology space. &Ouml;ssur improves people&rsquo;s mobility through the delivery of Prosthetics, Bracing &amp; Supports, and accompanying patient care. Headquartered in Iceland, the company employs over 4,000 people located across 36 countries worldwide. &Ouml;ssur has extensive operations in the Americas, Europe, and Asia, as well as&nbsp;distributors in other markets.&nbsp;&nbsp;
HC Andersen Capital receives payment from &Ouml;ssur for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 15:00, 24 October 2023.

HC Andersen Capital

Össur - Presentation of Q3 2023

Incap

Incap India’s production and testing director interviewed

AKTIER MED FRIIS - UGE 46 2025

Nibe Industrier

NIBE, Audiocast, Q3'25

Egetis Therapeutics

Egetis Therapeutics, Audiocast, 2025

Novo Nordisk

Bavarian Nordic

SKAKO

BioPorto

Vestas Wind Systems

Zealand Pharma

Ørsted

Royal Unibrew

HCA Morgenbørs 14/11 - Overvejende negative markeder og fokus på Bavarian Nordic

Össur - Presentation of Q3 2023

Embla Medical

Seneste videoer

Privatlivspræferencer